Is AVXL or AVTX more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% Avalo Therapeutics N/A -97.54% -72.42%

Which has better valuation & earnings, DSGN or AVXL?

Design Therapeutics is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A

Is DSGN or AVXL more profitable?

Design Therapeutics' return on equity of -33.07% beat Anavex Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Anavex Life Sciences N/A -38.76% -35.01%

Which has stronger valuation & earnings, REPL or AVXL?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.38 N/A Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A

Is REPL or AVXL more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Anavex Life Sciences N/A -38.76% -35.01%

Anavex Life Sciences (AVXL) Competitors

$2.43 +0.08 (+3.40%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.46 +0.03 (+1.23%)

As of 07/14/2026 05:19 PM Eastern

Compare

AVXL vs. AVTX, KURA, DSGN, PHAR, and REPL

Should you buy Anavex Life Sciences stock or one of its competitors? MarketBeat compares Anavex Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anavex Life Sciences include Avalo Therapeutics (AVTX), Kura Oncology (KURA), Design Therapeutics (DSGN), Pharming Group (PHAR), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.

How does Anavex Life Sciences compare to Avalo Therapeutics?

Anavex Life Sciences (NASDAQ:AVXL) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Avalo Therapeutics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Avalo Therapeutics and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Avalo Therapeutics' score of 0.65 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anavex Life Sciences	Very Positive
Avalo Therapeutics	Positive

Anavex Life Sciences' return on equity of -38.76% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Avalo Therapeutics	N/A	-97.54%	-72.42%

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 777.91%. Avalo Therapeutics has a consensus target price of $45.80, suggesting a potential upside of 148.64%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Anavex Life Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Anavex Life Sciences has higher earnings, but lower revenue than Avalo Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Avalo Therapeutics	$60K	16,138.99	-$78.26M	-$5.46	N/A

Summary

Anavex Life Sciences beats Avalo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Kura Oncology?

Anavex Life Sciences (NASDAQ:AVXL) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Anavex Life Sciences has higher earnings, but lower revenue than Kura Oncology. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Kura Oncology	$67.48M	14.79	-$278.67M	-$3.35	N/A

31.6% of Anavex Life Sciences shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Kura Oncology had 7 more articles in the media than Anavex Life Sciences. MarketBeat recorded 8 mentions for Kura Oncology and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Kura Oncology's score of 1.07 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anavex Life Sciences	Very Positive
Kura Oncology	Positive

Anavex Life Sciences presently has a consensus price target of $21.33, suggesting a potential upside of 777.91%. Kura Oncology has a consensus price target of $25.46, suggesting a potential upside of 126.53%. Given Anavex Life Sciences' higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Anavex Life Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Anavex Life Sciences has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Anavex Life Sciences' return on equity of -38.76% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Kura Oncology	-411.19%	-141.95%	-43.28%

Summary

Anavex Life Sciences beats Kura Oncology on 10 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Design Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 20.70%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 777.91%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Design Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

In the previous week, Design Therapeutics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Design Therapeutics and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Design Therapeutics' score of 0.94 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Design Therapeutics	Positive
Anavex Life Sciences	Very Positive

Design Therapeutics' return on equity of -33.07% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Design Therapeutics is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Summary

Design Therapeutics beats Anavex Life Sciences on 9 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pharming Group has a net margin of 3.30% compared to Anavex Life Sciences' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Pharming Group has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Pharming Group presently has a consensus price target of $38.33, indicating a potential upside of 185.86%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 777.91%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Pharming Group had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for Pharming Group and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Pharming Group's score of 1.77 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Pharming Group	Very Positive
Anavex Life Sciences	Very Positive

Pharming Group has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.52	$2.85M	$0.16	83.81
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Summary

Pharming Group beats Anavex Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Replimune Group had 4 more articles in the media than Anavex Life Sciences. MarketBeat recorded 5 mentions for Replimune Group and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Replimune Group's score of 0.93 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Replimune Group	Positive
Anavex Life Sciences	Very Positive

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Replimune Group presently has a consensus target price of $8.13, indicating a potential downside of 17.68%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 777.91%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Replimune Group has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Anavex Life Sciences' return on equity of -38.76% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Summary

Anavex Life Sciences beats Replimune Group on 10 of the 13 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$217.78M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-5.28	20.98	27.01	24.38
Price / Sales	N/A	311.10	522.34	91.89
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	2.21	8.54	10.80	6.33
Net Income	-$46.38M	$23.83M	$3.59B	$331.02M
7 Day Performance	-10.00%	-2.77%	-1.49%	-0.33%
1 Month Performance	-2.80%	5.85%	2.79%	-1.29%
1 Year Performance	-77.64%	52.15%	28.56%	21.30%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	2.8153 of 5 stars	$2.43 +3.4%	$21.33 +777.9%	-78.8%	$217.78M	N/A	N/A	40	Positive News Upcoming Earnings
AVTX Avalo Therapeutics	2.7849 of 5 stars	$19.96 +5.9%	$45.80 +129.5%	+275.9%	$990.34M	$60K	N/A	40
KURA Kura Oncology	2.8122 of 5 stars	$11.04 -0.5%	$25.46 +130.6%	+77.0%	$985.40M	$67.48M	N/A	130	News Coverage Positive News
DSGN Design Therapeutics	2.0918 of 5 stars	$14.85 -5.1%	$16.50 +11.1%	+241.8%	$976.83M	N/A	N/A	40	News Coverage
PHAR Pharming Group	3.451 of 5 stars	$14.31 +3.9%	$38.33 +167.9%	+29.6%	$972.51M	$376.13M	89.44	280	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. AVTX, KURA, DSGN, PHAR, and REPL

How does Anavex Life Sciences compare to Avalo Therapeutics?

Summary

How does Anavex Life Sciences compare to Kura Oncology?

Summary

How does Anavex Life Sciences compare to Design Therapeutics?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Summary

How does Anavex Life Sciences compare to Replimune Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. AVTX, KURA, DSGN, PHAR, and REPL

How does Anavex Life Sciences compare to Avalo Therapeutics?

Do institutionals and insiders have more ownership in AVXL or AVTX?

Does the media refer more to AVXL or AVTX?

Is AVXL or AVTX more profitable?

Do analysts prefer AVXL or AVTX?

Which has more risk & volatility, AVXL or AVTX?

Which has stronger earnings & valuation, AVXL or AVTX?

Summary

How does Anavex Life Sciences compare to Kura Oncology?

Which has better earnings and valuation, AVXL or KURA?

Do institutionals & insiders have more ownership in AVXL or KURA?

Does the media refer more to AVXL or KURA?

Do analysts rate AVXL or KURA?

Which has more risk & volatility, AVXL or KURA?

Is AVXL or KURA more profitable?

Summary

How does Anavex Life Sciences compare to Design Therapeutics?

Do analysts recommend DSGN or AVXL?

Do insiders & institutionals have more ownership in DSGN or AVXL?

Which has more risk & volatility, DSGN or AVXL?

Does the media refer more to DSGN or AVXL?

Is DSGN or AVXL more profitable?

Which has better valuation & earnings, DSGN or AVXL?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Do insiders & institutionals believe in PHAR or AVXL?

Is PHAR or AVXL more profitable?

Which has more risk & volatility, PHAR or AVXL?

Do analysts recommend PHAR or AVXL?

Does the media refer more to PHAR or AVXL?

Which has better earnings and valuation, PHAR or AVXL?

Summary

How does Anavex Life Sciences compare to Replimune Group?

Does the media refer more to REPL or AVXL?

Which has stronger valuation & earnings, REPL or AVXL?

Do insiders and institutionals believe in REPL or AVXL?

Do analysts recommend REPL or AVXL?

Which has more risk and volatility, REPL or AVXL?

Is REPL or AVXL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools